Funded Biotechnology Startups in Brooklyn
Brooklyn's biotechnology funding activity, based on the 13 companies shown, ranges from a $500K debt financing by Girihlet in March 2022 to OpenTrons' $200…
Brooklyn's biotechnology funding activity, based on the 13 companies shown, ranges from a $500K debt financing by Girihlet in March 2022 to OpenTrons' $200M Series C in September 2021. The dataset covers rounds closed between late 2021 and September 2025, with Cresilon, Inc.'s $17M venture deal the most recent entry.
A notable feature of the recent deal flow is stage opacity: five of the 13 rounds carry either a generic "Series Unknown" label or no stage designation — including Epi One ($2M, December 2024), Xylyx Bio ($3M, September 2024), and Auxilius ($10M, March 2024). Identified milestones span the full venture ladder, from Seed (Melonfrost at $7M, Kepler at $8M) through Series A (AlgiKnit at $13M, Kingdom Supercultures at $25M), Series B (Kinnos at $15M), and Series C (OpenTrons at $200M), pointing to a segment that supports companies at multiple growth stages rather than concentrating at any single one.
Most recent rounds
13 shownRelated listings
Frequently asked
What are the largest recent rounds among Brooklyn biotech companies in this dataset?
OpenTrons raised $200M in a Series C in September 2021, the largest round shown. Kingdom Supercultures follows with a $25M Series A in October 2021, and Cresilon, Inc. closed a $17M venture round in September 2025 as the most recent entry in the list.
What is the most recent funding event in this dataset?
Cresilon, Inc. closed a $17M venture round on September 8, 2025. The next most recent are Epi One ($2M, December 2024) and Xylyx Bio ($3M, September 2024).
How active was Brooklyn biotech fundraising in 2024?
Five companies closed rounds dated within 2024: Caladan Bio ($5M, February), First Wave BioPharma ($4M, March), Auxilius ($10M, March), Xylyx Bio ($3M, September), and Epi One ($2M, December). All five rounds fall in the $2M–$10M range.
What round stages are represented, and how many are undisclosed?
Of the 13 companies shown, eight have an identifiable stage: two Seed rounds (Melonfrost, Kepler), two Series A (AlgiKnit, Kingdom Supercultures), one Series B (Kinnos), one Series C (OpenTrons), one debt financing (Girihlet), and one Venture–Series Unknown (Cresilon). The remaining five carry either a generic "Series Unknown" label or no stage data at all.
What is the deal size range across these Brooklyn biotech rounds?
Disclosed round sizes span from Girihlet's $500K debt financing in March 2022 to OpenTrons' $200M Series C in September 2021. Excluding those two outliers, the remaining 11 rounds cluster between $2M and $25M.
Which companies raised Seed rounds, and at what size?
Kepler raised an $8M Seed in July 2022 and Melonfrost raised a $7M Seed in January 2023 — both represent early-stage Brooklyn biotech commitments in the $7–8M band.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.